Improdia is Monitoring the Immune Status

Improdia is an innovative, diagnostic company that is developing a simple blood test, that through monitoring the immune status of cancer patients predicts efficiency of immunotherapy when combined with cannabis, it also identifies diabetic patients at risk to develop future complications.

Proof of Concept
Biomarkers
The Test Kit
The Need
Current Situation

Miriam Lerner M.Sc.

CoCEO, CTO

Miriam Lerner M.Sc.

CoCEO, CTO

Miriam Lerner

Received her MSc in applied microbiology from the Hebrew University of Jerusalem. For over 20 years she has been involved in the R&D of diagnostic technologies, previously holding senior management positions in 2 companies from their establishment stage. She is experienced in leading project and research teams, as well as in managing QMS. Miriam has co-authored several scientific publications relating to her research.

Gil Pogozelich Ph.D.

Chairman

Gil Pogozelich Ph.D.

Chairman

Highly experienced, for 20 years has been leading successful technology startups. Now specializes in the development, integration and commercialization of Life Science technologies, with emphasis on the field of personalized medicine.

Prof. Dedi Meiri

Consultant

Prof. Dedi Meiri

Consultant

Lecturer, researcher and a member of the Technion faculty in the field of Cancer Biology and Cannabinoid Research- technological and business entrepreneurship, medical implications and methods of growth. He holds a master’s degree in biochemistry, a doctorate in plant biotechnology from Tel Aviv University and a post-doctorate from the Cancer Institute in Toronto. He has published five articles on pancreatic cancer, ovarian cancer, and cancerous metastasis

Dr. Roy Eldor, M.D.

Consultant

Dr. Roy Eldor, M.D.

Consultant

Director of the Diabetes Unit in the institute for Endocrinology, Metabolism and Hypertension, in the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel and the director of the Central District Diabetes Clinic,  Leumit HMO, Israel. Endocrinologist, internist and researcher with over twenty years of clinical, academic and scientific experience. Principal Scientist in Late Stage Development- Clinical Research Diabetes & Endocrinology, Merck Research Laboratories (MRL), Rahway, NJ, USA. Recognized expert, with over 40 peer reviewed papers and book chapters and invited speaker in international meetings.

Prof.  Michal Baniyash

Inventor

Prof.  Michal Baniyash

Inventor

Received her Ph.D. in Immunology from the Weizmann Institute of Science, currently a lecturer and principle investigator in the Department of Immunology and Cancer Research at the Hebrew University of Jerusalem, with more than 20 years of experience leading immunological  research on mechanisms and clinical implications of chronic inflammation and suppression of the immune system in various diseases the discovery of new molecules in normal conditions and chronic diseases. She has over 50 publications in prestigious medical journals and numerous inventions on the field of biomarkers.

Raphael Nir Ph.D.

Co-Founder

Raphael Nir Ph.D.

Co-Founder

Received his Biotechnology PhD from Tel-Aviv University and Master in engineering management. Partner at Goldman-Hirsh, with over 28 years of providing  experience commercializing recombinant cytokines and pre-clinical contract research services. A scientist, entrepreneur and angel investor with over 27 years of experience commercializing recombinant cytokines and pre-clinical contract research services. He is the co-founder of two pre-clinical contract research organizations: SBH Sciences and Woodland Biosciences; and three biotechnology companies: Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics.